PAUL SCHIMMEL
CIK 1236447 · last filed 2026-05-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$216.38M
Companies
7
Total Filings
77
Lifetime Open-Market Net
-$8.62M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ATYR | Director | 1,421,913 | $0.48 | $682.6K | $49.6K | 2 | 2026-05-28 |
| LIFE | Director | 688,033 | $19.62 | $13.50M | $6.76M | 38 | 2025-10-09 |
| Forte Biosciences, Inc. (TOCA) Delisted | Director | 1,806 | — | — | $100.0K | 4 | 2019-10-04 |
| ALNY | Director | 316,996 | $286.88 | $90.94M | -$15.34M | 27 | 2019-07-02 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Director | 352,022 | — | — | -$195.6K | 2 | 2007-12-04 |
| ALKS | Director | 360,600 | $48.30 | $17.42M | $0 | 1 | 2007-06-19 |
| RGEN | Director | 665,106 | $141.10 | $93.85M | $0 | 2 | 2007-06-18 |
Recent Filings · Page 7 of 8
77 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-06-10 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2012-06-25 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2012-02-23 | ALNY | Buy (P) | +93,023 | $1000.0K | EDGAR |
| 2011-06-13 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2010-06-04 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2009-09-11 | ALNY | Sell (S) | −45,600 | -$1.01M | EDGAR |
| 2009-09-09 | ALNY | Sell (S) | −29,400 | -$647.5K | EDGAR |
| 2009-06-12 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2008-06-05 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2007-12-04 | Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Mixed | +15,282 | -$184.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.